Question: How should atorvastatin treatment be managed for a patient with the SLCO1B1 *5/*5 genotype?

Answer: According to the CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9, a patient with the SLCO1B1 *5/*5 genotype is predicted to have poor function of the SLCO1B1 gene. This may increase the risk for developing atorvastatin-induced myopathy. It is recommended to prescribe a starting dose of atorvastatin ≤20mg and adjust doses based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. However, it's important to consult a clinical pharmacist for more information.

{"Sources": "CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9"}
Sources:
page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='atorvastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='pitavastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='of increased atorvastatin response. Int J Mol Sci 2011;12:5815-27.14. Puccetti L et al. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.15. Lee YJ et al. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010;48:36-45.16. Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.17. Mega JL et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5.18. He YJ et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009;405:49-52.19. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005;5:352-8.Date 18-05-2020SLCO1B1 521TC: fluvastatine4059NO action is required for this gene-drug interaction.The gene variation increases the plasma concentration of fluvastatin, but there is insufficient evidence to prove an effect on efficacy or side effects.Literature:1. Hirvensalo P et al. Enantiospecific pharmacogenomics of fluvastatin. Clin Pharmacol Ther 2019;106:668-80.2. Mori D et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet 2019;34:78-86.3. Xiang Q et al. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenet Genomics 2018;28:261-7.4. Meyer zu Schwabedissen HE et al. Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}


Question: For a patient with SLCO1B1 decreased function, what are the CPIC recommendations for simvastatin use?

Answer: According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, a patient with SLCO1B1 decreased function is at an increased risk for developing simvastatin-induced myopathy. The CPIC recommends prescribing an alternative statin depending on the desired potency. If simvastatin therapy is warranted, the dose should be limited to less than 20mg per day. It is advised to consult a clinical pharmacist for more information {"Sources": "CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9"}.


Sources:
page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='replaces the 2012 and 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for SLCO1B1  \nand simvastatin-  induced myopathy.\nIn 2012, the\xa0 Clinical Pharmacogenetics Implementation \nConsortium (CPIC) published a gene-  based prescribing guideline \nfor simvastatin based on SLCO1B1  genotype,1 and this guideline \nwas updated in 2014.2 The current document replaces the original \n2012 guideline and the 2014 update. New to this guideline are the \naddition of recommendations for CYP2C9  and ABCG2  and addi -\ntion of recommendations for all statins. We summarize literature supporting how SLCO1B1 , ABCG2 , and CYP2C9  genotype test \nresults should be applied to optimize new or existing statin ther -\napy to reduce the risk of statin-  associated musculoskeletal symp -\ntoms (SAMS). This CPIC document serves as a guide for selecting \nthe most appropriate statin and the optimal dose if  pharmacoge -\nnetic test results are available (not whether to perform pharmacog -' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 45  (237) Shin, J., Pauly, D.F., Pacanowski, M.A., Langaee, T., Frye, R.F. & Johnson, J.A. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy  31, 942-50 (2011).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='3 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE OF CONTENTS CPIC Updates.................................................................................................................................. 4 Literature Review ............................................................................................................................ 4 Available Genetic Test Options ...................................................................................................... 5 Linking genetic variability to variability in drug-related phenotypes ............................................ 6 Levels of evidence .......................................................................................................................... 9 Strength of dosing recommendations ............................................................................................ 10 Other Considerations' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 34  (39) Stein, C.M., Sadeque, A.J., Murray, J.J., Wandel, C., Kim, R.B. & Wood, A.J. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clinical pharmacology and therapeutics  69, 317-23 (2001). (40) Capone, D., Stanziale, P., Gentile, A., Imperatore, P., Pellegrino, T. & Basile, V. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. Am J Nephrol  19, 411-5 (1999). (41) Lepre, F., Rigby, R., Hawley, C., Saltissi, D., Brown, A. & Walsh, Z. A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. Clin Transplant  13, 520-5 (1999). (42) Pflugfelder, P.W., Huff, M., Oskalns, R., Rudas, L. & Kostuk, W.J. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant  14, 613-22 (1995). (43)' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 40  (148) Bailey, K.M. et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet  3, 276-85 (2010). (149) Hopewell, J.C. et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J  34, 982-92 (2013). (150) Dou, Y., Zhu, X., Wang, Q., Tian, X., Cheng, J. & Zhang, E. Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins. Ann Lab Med  35, 329-35 (2015). (151) Li, J.H., Suchindran, S., Shah, S.H., Kraus, W.E., Ginsburg, G.S. & Voora, D. SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. Pharmacogenomics  16, 449-58 (2015). (152) Kitzmiller, J.P., Luzum, J.A.,' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='10 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  STRENGTH OF DOSING RECOMMENDATIONS CPIC’s dosing recommendations are based on weighing the evidence from a combination of preclinical functional and clinical data (Supplemental Tables S1-S3) as well as on some existing disease-specific consensus guidelines (30). Some of the factors that are considered in evaluating the evidence supporting dosage recommendations include: in vivo clinical outcome data for statins, in vivo pharmacokinetic and pharmacodynamic data for statins, in vitro enzyme/transporter activity of expressed wild-type or variant-containing gene, in vitro enzyme activity from tissues isolated from individuals of known genotypes, in vivo pre-clinical pharmacokinetic and pharmacodynamic studies, and in vitro studies of protein stability.   Overall, the therapeutic recommendations are simplified to allow rapid interpretation by clinicians. CPIC uses a slight modification of a transparent and simple' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='Page 27 of 28Accepted Manuscript\n27 \n Figure 4 . Indications for  SLCO1B1  genotyping for simvastatin treatment. Proposed therapeutic strategy as a \nfunction of risk factors and current CPIC and FDA guidelines  [23,24].  \n 80 mg/J  \nMajor toxic risk  20  mg/J \nModerate toxic risk  \nAvoid combining with CYP3A and/or OATP1B1:  \n(Amiodarone,  amlodipine  ,  verapamil  ,  diltiazem  ,  gemfibrozil  ,  \nciclosporine, azoles  antifungals  ,  antiproteases  , …) \nA priori  SLCO1B genotyping  ? (potentially  useful test)  Dosage to avoid  \n(except  after prior 12 -month \nsatisfactory tolerance  \n SLCO1B1  genotype  \nunknown  \n 40 mg/J  \nIntermediary risk  \nTT TC CC \nLower simvastatin dose to 20 mg/d  \n+ CPK assay  \nOR therapeutic alternative  \n1) Fluvastatine  \n2) Lovastatine  \n3) Rosuvastatine  \n4) Atorvastatine  \n5) Pravastatine  \nMuscle toxicity:  \n discontinue treatment  \nSLCO1B1 genotyping  \nfor explanation  \n(potentially  useful test  Initiation of simvastatin treatement' metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien Lamoureux,Thomas Duflot. The French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}
page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='Page 15 of 28Accepted Manuscript\n15 \n - Prescription guidelines : data on SLCO1B1  polymorphisms were recently introduced into the \nwarnings and precautions  paragraph for certain statins such as simvastatin. The higher risk of \nmyotoxicity associat ed with the presence of the rs4149056 C allele is mentioned. The FDA \ncurrently recommends avoiding doses of 80 mg/d for simvastatin because of the higher risk of \nmyotoxicity [27]. In general, marketing approval labeling advises against combining statins wi th \nOATP1B1 and/or CYP3A4/5 inhibitors . \n- Recommendations from learned societies : Internationally, the CPIC recommends taking into \naccount the SLCO1B1  genotype together with the dose, the type of statin, and co -medications for \nassessing the risk of  potential statin toxicity (Figure 4).  In agreement with the FDA guidelines, the \nCPIC recommends: i) against prescribing simvastatin at 80 mg/d the first year of treatment (and' metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien Lamoureux,Thomas Duflot. The French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}


Question: How should rosuvastatin treatment be adjusted for a patient with an ABCG2 poor function phenotype?

Answer: The adjustment of rosuvastatin treatment for a patient with an ABCG2 poor function phenotype can depend on various factors, including the patient's SLCO1B1 phenotype. According to the CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9, a patient with an ABCG2 poor function phenotype may be at an increased risk of rosuvastatin-induced myopathy. It is generally recommended to prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. However, because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. It is advised to consult a clinical pharmacist for more information. 

Please note that this information is based on general guidelines and the specific needs and conditions of the patient should be considered by a healthcare professional. 

{"Sources": "CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9"}
Sources:
page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}


Question: According to CPIC guidelines, for a patient with  CYP2C9 *3/*3 diplotype, what are the recommendations for fluvastatin dosage?

Answer: Based on the information provided in the prompt, specific dosage recommendations for a patient with a CYP2C9 *3/*3 diplotype (which would likely classify them as a CYP2C9 poor metabolizer) are not explicitly stated. However, it is generally recommended that CYP2C9 poor metabolizers should avoid fluvastatin doses greater than 20 mg. If higher doses are required for desired efficacy, an alternative statin should be considered. If fluvastatin therapy is warranted, consider combination therapy of fluvastatin (20 mg) plus a nonstatin lipid-lowering agent. Please consult a clinical pharmacist for more information {"Sources": "Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072."}.
Sources:
page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1017Table 4 Dosing recommendations for fluvastatin based on CYP2C9 phenotype in adults\nPhenotype Implication Dosing recommendationsClassification of \nrecommendationsaConsiderations\nCYP2C9 normal metabolizer Normal exposure Prescribe desired starting dose and \nadjust doses of fluvastatin based on \ndisease-  specific guidelinesStrong The potential for drug–  drug \ninteractions and dose limits \nbased on renal and hepatic \nfunction should be evaluated prior \nto initiating a statin\nCYP2C9 intermediate metabolizer AS \nof 1 and 1.5Increased fluvastatin exposure as \ncompared with normal metabolizer, \nwhich may translate to increased \nmyopathy riskPrescribe ≤40\xa0mg per day as a \nstarting dose and adjust doses of \nfluvastatin based on disease-  specific \nguidelines. If dose >40\xa0mg needed \nfor desired efficacy, consider an \nalternative statin or combination \ntherapy (i.e., fluvastatin plus nonstatin' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='phenotype are available in Table\xa0 4. Genetic variations in CYP2C9  \nare associated with increased exposure to fluvastatin ( Table\xa0 S3), \nbut the pharmacokinetics or pharmacodynamics of other statins \nare not affected.\nCYP2C9 IMs should avoid fluvastatin doses greater than 40\xa0mg \nwhile CYP2C9 PMs should avoid doses greater than 20 mg. If \nhigher doses are required for desired efficacy, an alternative statin \nshould be considered. If fluvastatin therapy is warranted, consider \ncombination therapy of fluvastatin (40 mg in IMs and 20 mg in \nPMs) plus a nonstatin lipid-  lowering agent.Combinatorial gene-  based recommendations.  Although specific \ncombinations of SLCO1B1  with ABCG2  or CYP2C9  genotypes \nare likely to result in additive effects on the pharmacokinetic \nproperties of rosuvastatin or fluvastatin, respectively, little \ninformation is available on how to adjust initial doses based on \ncombined genotype information.33 Combinatorial gene-  based' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='recommendations generated by extrapolating evidence supporting \nthe single gene associations and assuming that they are additive, \nare provided for rosuvastatin in Table\xa0 5 and fluvastatin in \nTable\xa0 6. Because there are limited clinical or pharmacokinetic \ndata regarding these combinatorial phenotypes, pharmacotherapy \nrecommendations are classified as optional for the high-  risk \nphenotype groups (e.g., SLCO1B1 no function plus ABCG2 \nno function). In the case of fluvastatin recommendations for \nCYP2C9 poor metabolizers who also have SLCO1B1 decreased \nor poor function, we recommend prescribing an alternative agent \nrather than prescribing a lower dose based on the available dosage \nforms (no dosage form less than 20\xa0mg is available for fluvastatin).\nGeneral guidance for patients already receiving statin therapy.  The \ntherapeutic recommendations described herein predominately \napply to a new or a revision (dose or type) to statin prescription.' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 normal metabolizer,Post-test,"This patient is predicted to be a CYP2C9 normal metabolizer and to have SLCO1B1 poor function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose > 40mg is needed for desired efficacy, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='25 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S3.  EVIDENCE LINKING CYP2C9 GENOTYPE WITH STATIN PHENOTYPE Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References  Level of Evidence In vitro Fluvastatin is metabolized in human liver by several enzymes, with CYP2C9 being the most important, followed by CYP3A4 and CYP2C8. Fischer, et al. (1999) (187) Toda, et al. (2009) (188) Hirvensalo, et al. (2019) (119)  High In vitro Fluvastatin is a potent inhibitor of CYP2C9. Transon, et al. (1996) (189) Cohen, et al. (2000) (190) Moderate In vitro CYP2C9*2, *3 were associated with reduced clearance of fluvastatin enantiomers in vitro. Hirvensalo, et al. (2019) (119) Moderate In vitro Fluvastatin and lovastatin increased CYP2C9 protein level in endothelial cells. Bertrand-Thiebault, et al. (2007) (191) Weak Clinical CYP2C9*2, *3 are not significantly associated with lipid-lowering response to fluvastatin. Kirschheiner,' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}


Question: My patient has decreased function in SLCO1B1, should I adjust her Livalo dosage? Or should I prescribe another statin?

Answer: Based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, a patient with decreased function in SLCO1B1 may have increased exposure to pitavastatin (Livalo), which could potentially increase the risk of myopathy. It is recommended to prescribe a starting dose of ≤2mg and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. However, it's important to consult a clinical pharmacist for more personalized advice. 

Please note that this information is based on pharmacogenetic testing and should be considered alongside other factors such as treatment goals, potential drug interactions, and the patient's overall health status. 

{"Sources": "Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072."}


Sources:
page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='possible SLCO1B1 decreased \nfunctionPrescribe desired starting dose \nand adjust doses of rosuvastatin \nbased on disease-  specific and \npopulation-  specific guidelines. \nPrescriber should be aware \nof possible increased risk for \nmyopathy especially for doses >20 \nmg. STRONGPrescribe desired starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific \nguidelines. Prescriber should \nbe aware of possible increased \nrisk for myopathy especially for \ndoses >20 mg. MODERATEPrescribe ≤10 mg as a \nstarting dose and adjust \ndoses of rosuvastatin based \non disease-  specific and \npopulation-  specific guidelines. \nIf dose >10 mg needed for \ndesired efficacy, consider \nan alternative statin or \ncombination therapy (i.e., \nrosuvastatin plus nonstatin \nguideline-  directed medical \ntherapy).3 OPTIONAL\nSLCO1B1 poor function Prescribe ≤20 mg as a starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='and decreased function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins)Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nPitavastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased pitavastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤2 mg as a starting dose and adjust \ndoses of pitavastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for doses \n>1\xa0mg. If dose >2 mg needed for desired efficacy, \nconsider an alternative statin (see Figure\xa01 \nfor recommendations for alternative statins)' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}


Question: My patient has ABCG2 Poor Function and SLCO1B1 Decreased function. Do I need to make any changes to his current prescription? He takes Crestor.

Answer: Based on the information provided, the patient has ABCG2 poor function and SLCO1B1 decreased function. Crestor is the brand name for rosuvastatin. According to the CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9, this patient may be at an increased risk of rosuvastatin-induced myopathy. It is recommended to prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. However, this is a general guideline and individual patient factors may vary. Please consult a clinical pharmacist for more information.

{"Sources": "CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9"}
Sources:
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}


Question: My patient is on fluvastatin currently, his pgx results indicate CYP2C9 intermediate metabolizer and SLCO1B1 normal function, what are CPIC guidelines? Provide citations.

Answer: According to the CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9, a patient who is a CYP2C9 intermediate metabolizer and has SLCO1B1 normal function may be at an increased risk of fluvastatin-induced myopathy. The recommended action is to prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. It is also advised to consult a clinical pharmacist for more information.

{"Sources": "CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9"}


Sources:
page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 normal metabolizer,Post-test,"This patient is predicted to be a CYP2C9 normal metabolizer and to have SLCO1B1 poor function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose > 40mg is needed for desired efficacy, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. Thise patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 decreased function. Thise patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score n/a,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}


Question: Do I need to make any dosing changes for rosuvastatin for ABCG2 poor function and SLCO1B1 normal function?

Answer: Based on the CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9, a patient with ABCG2 poor function and SLCO1B1 normal function may be at an increased risk of rosuvastatin-induced myopathy. It is recommended to prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. However, it is important to consult a clinical pharmacist for more personalized advice. 

{"Sources": "CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9"}
Sources:
page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}


Question: What are Lescol XL dosing guidelines for SLCO1B1 decreased function and CYP2C9 poor metabolizer?

Answer: Based on the CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9, a patient with SLCO1B1 decreased function and CYP2C9 poor metabolizer status may be at an increased risk of fluvastatin-induced myopathy. For such patients, it is recommended to prescribe an alternative statin depending on the desired potency. However, it's important to consult a clinical pharmacist for more personalized information. 

Please note that this information is based on pharmacogenetic testing and should be used in conjunction with other clinical factors such as patient's overall health, other medications, and treatment goals. 

{"Sources": "CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9"}
Sources:
page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 normal metabolizer,Post-test,"This patient is predicted to be a CYP2C9 normal metabolizer and to have SLCO1B1 poor function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose > 40mg is needed for desired efficacy, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 decreased function. Thise patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}


Question: My patient takes atorvastatin, his recent pharmacogenetic testing results shows that he has SLCO1B1 possible decreased function. Can he continue taking atorvastatin? Do I need to adjust his dosage? If so, can you give me some recommendations? Please cite sources.

Answer: Based on the information provided, your patient has a possible decreased function of the SLCO1B1 gene. According to the CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9, this may increase the risk of atorvastatin-induced myopathy. It is recommended to prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. However, it's important to consult a clinical pharmacist for more personalized advice.

{"Sources": "CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9"}


Sources:
page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='of increased atorvastatin response. Int J Mol Sci 2011;12:5815-27.14. Puccetti L et al. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.15. Lee YJ et al. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010;48:36-45.16. Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.17. Mega JL et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5.18. He YJ et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009;405:49-52.19. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='T.A., Naveed, A.K., Farooqi, Z.R. & Khan, S. Effects of two functionally important SLCO1B1 gene polymorphisms on pharmacokinetics of atorvastatin. Pak J Pharm Sci  30, 1363-70 (2017). (104) Wang, Y. et al. The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people. Pharmazie  72, 365-8 (2017). (105) Woo, H.I., Kim, S.R., Huh, W., Ko, J.W. & Lee, S.Y. Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. Drug Des Devel Ther  11, 1135-46 (2017). (106) Lee, N. et al. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. Drug Metab Pharmacokinet  34, 387-95 (2019). (107) Tachibana-Iimori, R. et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet  19, 375-80 (2004).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}


Question: What are the consequences if my patient has SLCO1B1 decreased function and is on simvastatin?

Answer: Patients with SLCO1B1 decreased function are predicted to have an increased risk for developing simvastatin-induced myopathy. This is due to the role of the SLCO1B1 gene in the body's processing of simvastatin. If simvastatin therapy is warranted, it is recommended to limit the dose to less than 20mg per day. Alternatively, an alternative statin may be prescribed depending on the desired potency. It is advised to consult a clinical pharmacist for more information. 

Please note that this information is based on pharmacogenetic guidelines and the patient's overall health, other medications, and treatment goals should also be considered when making prescribing decisions. 

{"Sources": "CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9"}
Sources:
page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='simvastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}


Question: What does SLCO1B1 *5/*5 mean?

Answer: The SLCO1B1 *5/*5 diplotype corresponds to a phenotype known as SLC01B1 Poor Function. This means that the function of the SLCO1B1 gene, which plays a role in drug metabolism, is likely to be poor in individuals with this diplotype. In the context of Electronic Health Records (EHR), this diplotype is categorized as Abnormal/Priority/High Risk. However, it's important to note that this information alone is not sufficient to make treatment decisions. Other factors such as treatment goals, drug interactions, and the presence of other genetic variants (like ABCG2 and CYP2C9 for rosuvastatin and fluvastatin respectively) should also be considered. Always consult with a healthcare professional for medical advice.

{"Sources": "SLCO1B1 Diplotypes to Phenotypes Mapping"}
Sources:
page_content='Patients with the SLCO1B1 Diplotype *5/*27 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*7 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*5 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*8 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*33 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*37 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*6 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*11 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*42 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*10 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}


Question: How common is SLCO1B1 *1/*5?

Answer: I'm sorry, but I do not have the specific information on the prevalence of the SLCO1B1 *1/*5 diplotype. The frequency of specific diplotypes can vary widely among different populations. For accurate information, please consult a healthcare professional or a reliable genetic database.
Sources:
page_content='Patients with the SLCO1B1 Diplotype *5/*5 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*23 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*27 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*15 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*28 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*8 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*11 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*47 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*33 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *5/*37 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}


Question: What do pharmacogenetic results *1/*2 for the CYP2C9 gene mean?

Answer: The CYP2C9 gene is involved in the metabolism of various drugs. Different variants of this gene can affect how well these drugs are processed in the body. The *1/*2 genotype for the CYP2C9 gene indicates that the individual has one normal-function allele (*1) and one decreased-function allele (*2). 

This genotype typically corresponds to an Intermediate Metabolizer phenotype. Intermediate metabolizers have a reduced metabolic capacity compared to normal metabolizers. This can affect the efficacy and side effects of drugs metabolized by the CYP2C9 enzyme. 

However, it's important to note that the impact of this genotype can vary depending on the specific drug and other factors such as the presence of other gene variants, overall health, age, and lifestyle. Therefore, the interpretation of this result should be done by a healthcare professional considering all these factors.

{"Sources": "CYP2C9 Diplotypes to Phenotypes Mapping"}
Sources:
page_content='CYP2C9 genotypes are not. Eur J Clin Pharmacol 2006;62:713-20.15. Visser LE et al. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther 2005;77:479-85.16. Schalekamp T et al. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 2004;76:409-17.17. Ufer M et al. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica 2004;34:847-59.18. Visser LE et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004;92:61-6.19. Visser LE et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004;14:27-33.20. Kirchheiner J et al. Effects of CYP2C9 polymorphisms on the' metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}
page_content='Patients with the CYP2C9 Diplotype *2/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CYP2C9 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the CYP2C9 Diplotype *1/*9  display a CYP2C9 Normal Metabolizer phenotype with an activity score of 2.0. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CYP2C9 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the CYP2C9 Diplotype *2/*2  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CYP2C9 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the CYP2C9 Diplotype *2/*4  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CYP2C9 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the CYP2C9 Diplotype *1/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CYP2C9 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the CYP2C9 Diplotype *2/*29  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CYP2C9 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CYP2C9 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the CYP2C9 Diplotype *2/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CYP2C9 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the CYP2C9 Diplotype *1/*29  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CYP2C9 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the CYP2C9 Diplotype *1/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CYP2C9 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the CYP2C9 Diplotype *1/*4  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CYP2C9 Diplotypes to Phenotypes Mapping'}


Question: What does a PGx result of *14/*14 for the gene SLCO1B1 mean?

Answer: A pharmacogenetic (PGx) result of *14/*14 for the gene SLCO1B1 indicates a diplotype that is associated with an increased function phenotype of the SLC01B1 protein. In the context of electronic health records (EHR), this diplotype is typically categorized as Normal/Routine/Low Risk. However, it's important to note that this information should be used in conjunction with other clinical factors and genetic test results, such as those for ABCG2 and CYP2C9, when considering the prescription of certain medications like rosuvastatin and fluvastatin. Always consult with a healthcare professional for personalized medical advice.

{"Sources": "SLCO1B1 Diplotypes to Phenotypes Mapping"}
Sources:
page_content='Patients with the SLCO1B1 Diplotype *14/*14 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *14/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *14/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *1/*14 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *14/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *14/*47 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *14/*15 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *14/*46 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *14/*31 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *14/*48 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *15/*34 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}
page_content='Patients with the SLCO1B1 Diplotype *13/*23 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}


Question: My patient has ABCG2 decreased function, should I adjust her Lipitor dosage? Or should I prescribe another statin?

Answer: Based on the information provided, the patient has a decreased function of the ABCG2 gene. However, the SLCO1B1 genotype of the patient is not mentioned. The SLCO1B1 gene also plays a significant role in the metabolism of statins, including Lipitor (atorvastatin). Without this information, it's not possible to provide a complete recommendation on whether to adjust the dosage of Lipitor or consider another statin. It's recommended to consult a clinical pharmacist or healthcare provider for further guidance. 

Please note that this advice is based on the patient's genetic information only. Other factors such as the patient's overall health, other medications they are taking, and their treatment goals should also be considered when making medication decisions. 

{"Sources": "CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9"}
Sources:
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='and decreased function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins)Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nPitavastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased pitavastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤2 mg as a starting dose and adjust \ndoses of pitavastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for doses \n>1\xa0mg. If dose >2 mg needed for desired efficacy, \nconsider an alternative statin (see Figure\xa01 \nfor recommendations for alternative statins)' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}


Question: For a patient with a CYP2C9 poor metabolizer, what are the recommendations for simvastatin dosage? Use CPIC guidelines.

Answer: Based on the CPIC guidelines, the information provided in the prompt does not specify the SLCO1B1 genotype of the patient. This information is crucial in providing a comprehensive recommendation for simvastatin dosage. The SLCO1B1 genotype can influence the risk of simvastatin-induced myopathy. Therefore, without this information, it's not possible to provide an accurate recommendation for simvastatin dosage for a patient who is a CYP2C9 poor metabolizer. It's recommended to consult a clinical pharmacist or healthcare provider for more information. 

{"Sources": "CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9"}
Sources:
page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 44  (219) Wang, D., Guo, Y., Wrighton, S.A., Cooke, G.E. & Sadee, W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J  11, 274-86 (2011). (220) Kivisto, K.T. et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics  14, 523-5 (2004). (221) Fiegenbaum, M. et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther  78, 551-8 (2005). (222) Hu, M., Mak, V.W., Xiao, Y. & Tomlinson, B. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics  14, 25-34 (2013). (223) Kolovou, G. et al. Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin. Open Cardiovasc Med J  8, 12-7 (2014). (224) Elens, L. et al. Novel CYP3A4' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='26 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Kirschheiner, et al. (2003) (192) Hirvensalo, et al. (2019) (119) Clinical CYP2C9*2 or *3 allele is associated with greater odds of developing fluvastatin-induced adverse effects (liver and muscle toxicity). Mirosevic, et al. (2013) (186) Moderate Unknown Statins, CYP2C9 genotypes are not significantly associated with muscle tox or lipid response to statins (simvastatin, fluvastatin, rosuvastatin). Zuccaro, et al. (2007) (193) Weak Clinical A case with liver cirrhosis who experienced fluvastatin-induced fatal rhabdomyolysis. This patient had been treated with simvastatin (20 mg/day) for coronary artery disease and was switched to fluvastatin (20 mg/day) 10 days before admission. Baek, et al. (2011) (194) Weak Clinical CYP2C9*3 is not associated with LDL response to rosuvastatin. Bailey, et al. (2010) (148) Moderate  Clinical CYP2C9*3 allele is associated with an increased concentration of pitavastatin. Zhou,' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 normal metabolizer,Post-test,"This patient is predicted to be a CYP2C9 normal metabolizer and to have SLCO1B1 poor function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose > 40mg is needed for desired efficacy, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='30 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Clinical  CYP3A4*22 is associated with cholesterol response to simvastatin. Elens, et al. (2011) (224) Ragia, et al. (2015) (225) Kitzmiller, et al. (2017) (152) Weak Clinical  CYP3A4*1G is not associated with cholesterol response to simvastatin. Gao, et al. (2008) (226) Hu, et al. (2013) (222) Weak Clinical  CYP3A4*1B is not associated with cholesterol response to simvastatin. Fiegenbaum, et al. (2005) (221) Weak Clinical  CYP3A4*4 is not associated with LDL lowering response to simvastatin but may affect percentage reductions in total cholesterol and triglycerides. Wang, et al. (2005) (227) Weak Clinical  CYP3A5*3 may be associated with higher simvastatin concentration. Kim, et al. (2007) (228) Kitzmiller, et al. (2014) (229) Choi, et al. (2015) (142) Luzum, et al. (2015) (143) Weak Clinical  CYP3A4*22 is associated with higher plasma simvastatin concentration compared to CYP3A4*1/*1. Kitzmiller, et al.' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='25 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S3.  EVIDENCE LINKING CYP2C9 GENOTYPE WITH STATIN PHENOTYPE Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References  Level of Evidence In vitro Fluvastatin is metabolized in human liver by several enzymes, with CYP2C9 being the most important, followed by CYP3A4 and CYP2C8. Fischer, et al. (1999) (187) Toda, et al. (2009) (188) Hirvensalo, et al. (2019) (119)  High In vitro Fluvastatin is a potent inhibitor of CYP2C9. Transon, et al. (1996) (189) Cohen, et al. (2000) (190) Moderate In vitro CYP2C9*2, *3 were associated with reduced clearance of fluvastatin enantiomers in vitro. Hirvensalo, et al. (2019) (119) Moderate In vitro Fluvastatin and lovastatin increased CYP2C9 protein level in endothelial cells. Bertrand-Thiebault, et al. (2007) (191) Weak Clinical CYP2C9*2, *3 are not significantly associated with lipid-lowering response to fluvastatin. Kirschheiner,' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='29 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S5.  EVIDENCE LINKING CYP3A4/5 GENOTYPE WITH STATIN PHENOTYPE  Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References  Level of Evidence Clinical CYP3A5*3/*3 genotype (6986A>G) is associated with simvastatin-induced muscle symptoms. Shek, et al. (2017) (134) Liu, et al. (2017) (91)  Weak Clinical  CYP3A5*3/*3 genotype (6986A>G) is more frequent in statin-intolerant cases. Shek, et al. (2018) (162) Weak Clinical CYP3A5*3/*3 genotype (6986A>G) is associated with simvastatin-induced liver symptoms. Shek, et al. (2017) (134) Weak Clinical When simvastatin-intolerant patients were switched to rosuvastatin, serious side effect were not observed and many of them carry CYP3A5*3/*3. Shek, et al. (2018) (162) Weak Clinical  CYP3A4 rs2740574 (G>A) G allele is associated with smaller risk of a dose decrease or switch to another drug during simvastatin and atorvastatin' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. Thise patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}


Question: If a patient's PGx results indicate  that they are a SLCO1B1 poor metabolizer, should I increase their Zocor dosing? Use established guidelines and cite references.

Answer: Based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for statins and SLCO1B1, ABCG2, and CYP2C9, patients with SLCO1B1 poor function are at an increased risk for developing simvastatin-induced myopathy. Therefore, it is generally recommended to prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, the dose should be limited. However, the exact dose limit is not specified in the prompt. Please consult a clinical pharmacist for more information. 

{"Sources": "CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9"}


Sources:
page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='lovastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}


Question: Is it advised by CPIC guidelines to consider alternative statins for patients with variants in the ABCG2 gene who are prescribed lovastatin?

Answer: The CPIC guidelines do not specifically mention the impact of ABCG2 gene variants on the prescription of lovastatin. The guidelines primarily focus on the SLCO1B1, ABCG2, and CYP2C9 genotypes and their influence on statin-associated musculoskeletal symptoms. However, the guidelines do not provide specific recommendations for lovastatin in the context of ABCG2 gene variants. It's important to note that individual patient factors, treatment goals, and potential drug interactions should also be considered when prescribing medications. For personalized advice, it is recommended to consult with a healthcare provider or a clinical pharmacist.

{"Sources": "Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072."}
Sources:
page_content='frequency, allele functionality, diplotype to phenotype tables have all been updated and reformatted and are now available at https://cpicpgx.org/guidelines/cpic-guideline-for-statins/   LITERATURE REVIEW We searched the PubMed database (1966 to July 2021) using the following keyword strategies: SLCO1B1: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (SLCO1B1 OR OATP1B1) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response OR reaction) NOT ("review"[Publication Type]) AND English[lang] AND ("2014/01/01"[PDAT] : "2021/07/20"[PDAT]) ABCG2: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (ABCG2 OR BCRP) AND (myopathy' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='to support the adoption of CPIC guidelines within an EHR.  Based on the capabilities of various EHRs and local preferences, we recognize that approaches may vary across organizations. Our intent is to synthesize foundational knowledge that provides a common starting point for incorporating the use of SLCO1B1, ABCG2 and CYP2C9 genotype results to guide statin use in an EHR.' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='replaces the 2012 and 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for SLCO1B1  \nand simvastatin-  induced myopathy.\nIn 2012, the\xa0 Clinical Pharmacogenetics Implementation \nConsortium (CPIC) published a gene-  based prescribing guideline \nfor simvastatin based on SLCO1B1  genotype,1 and this guideline \nwas updated in 2014.2 The current document replaces the original \n2012 guideline and the 2014 update. New to this guideline are the \naddition of recommendations for CYP2C9  and ABCG2  and addi -\ntion of recommendations for all statins. We summarize literature supporting how SLCO1B1 , ABCG2 , and CYP2C9  genotype test \nresults should be applied to optimize new or existing statin ther -\napy to reduce the risk of statin-  associated musculoskeletal symp -\ntoms (SAMS). This CPIC document serves as a guide for selecting \nthe most appropriate statin and the optimal dose if  pharmacoge -\nnetic test results are available (not whether to perform pharmacog -' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='lovastatin OR Caduet OR Vytorin) AND (CYP3A4 OR CYP3A5) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang] Using these search terms, 1023 publications were identified. Study inclusion criteria included publications that incorporated analyses for the association between SLCO1B1, ABCG2, CYP2C9, HMGCR, or CYP3A4/5 genotypes and statins pharmacokinetic parameters as well as clinical outcomes. Non-English manuscripts and reviews were excluded. Following the application of these inclusion and exclusion criteria, 197 publications were reviewed and included in the evidence table (Table S1 to S5).  AVAILABLE GENETIC TEST OPTIONS  Desirable characteristics of pharmacogenetic tests, including naming of alleles and test report contents, have been' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1021 6. Clinical Pharmacogenetics Implementation Consortium (CPIC). \nCPIC guideline for statins and SLCO1B1, ABCG2 and CYP2C9 . \n<https://cpicp  gx.org/guide  lines/  cpic- guide  line- for- stati ns/>. \nAccessed August 1, 2021 2021.\n 7. Pharmacogenetics and Pharmacogenomics Knowledge Base \n(PharmGKB). PGx Gene-  Specific Information Tables  <https://www.\npharm  gkb.org/page/pgxGe  neRef>.\n 8. PharmVar. Pharmacogene Variation Consortium  <https://www.\npharm  var.org/>. Accessed October 18, 2021.\n 9. Sangkuhl, K. et al . PharmVar GeneFocus: CYP2C9. Clin. \nPharmacol. Ther.  110, 662–  676 (2021).\n 10. Lee, C.R., Goldstein, J.A. & Pieper, J.A. Cytochrome P450 2C9 \npolymorphisms: a comprehensive review of the in - vitro and human \ndata. Pharmacogenetics  12, 251–  263 (2002).\n 11. Gaedigk, A. et al. The evolution of PharmVar. Clin. Pharmacol. Ther.  \n105, 29–  32 (2019).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='5 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang]  CYP2C9: (fluvastatin) AND (CYP2C9) HMGCR: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (HMGCR) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang] CYP3A4/5: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (CYP3A4 OR' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='3 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE OF CONTENTS CPIC Updates.................................................................................................................................. 4 Literature Review ............................................................................................................................ 4 Available Genetic Test Options ...................................................................................................... 5 Linking genetic variability to variability in drug-related phenotypes ............................................ 6 Levels of evidence .......................................................................................................................... 9 Strength of dosing recommendations ............................................................................................ 10 Other Considerations' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='23 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Lee, et al. (2013) (168) Kim, et al. (2017) (169) Kim, et al. (2019) (170) Clinical ABCG2 SNP rs2199936 is significantly associated with absolute LDL-C reduction. (rs2231142 (421C>A) is in LD with rs2199936 in the HapMap (CEU, r2=0.81)). Chasman, et al. (2012) (171)  High  Clinical ABCG2 rs2231142 (c.421C>A) is significantly associated with rosuvastatin exposure. Genotypes AC + AA are associated with increased exposure to rosuvastatin compared to CC. Zhang, et al. (2006) (172) Keskitalo, et al. (2009) (21) Zhou, et al. (2013) (173) DeGorter, et al. (2013) (22) Lee, et al. (2013) (168) Birmingham, et al. (2015) (174) Birmingham, et al. (2015) (101) Wan, et al. (2015) (175) Kim, et al. (2019) (170) Liu, et al. (2016) (176) Kashihara, et al. (2017) (177) Bai, et al. (2019) (23) Soko, et al. (2019) (178) Zhang, et al. (2020) (179) High' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='OPTIONALPrescribe an alternative statin \ndepending on the desired \npotency (see Table\xa02 and \nFigure\xa01 for recommendations \nfor alternative statins). \nOPTIONAL\nRating scheme described in the Supplemental Material . Classification of Recommendations in all caps.\nCPIC UPDATE' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1007The Clinical Pharmacogenetics Implementation \nConsortium Guideline for SLCO1B1, ABCG2, \nand CYP2C9 genotypes and Statin- Associated \nMusculoskeletal Symptoms\nRhonda M. Cooper- DeHoff1,2,†, Mikko Niemi3,4,5,†, Laura B. Ramsey6,7, Jasmine A. Luzum8,  \nE. Katriina T arkiainen3,4,5, Robert J. Straka9, Li Gong10, Sony T uteja11, Russell A. Wilke12, Mia W adelius13, \nEric A. Larson12, Dan M. Roden14,15, T eri E. Klein10, Sook W ah Y ee16, Ronald M. Krauss17, Richard M. T urner18, \nLatha Palaniappan19, Andrea Gaedigk20, Kathleen M. Giacomini16, Kelly E. Caudle21 and Deepak V oora22,*\nStatins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed \nmedications in the world. Statin-  associated musculoskeletal symptoms (SAMS) impact statin adherence and \nultimately can impede the long-  term effectiveness of statin therapy. There are several identified pharmacogenetic' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='offer guidance to achieve these objectives with diagrams that illustrate how point-of-care CDS should be entered into the EHR, example pre- and post-test alert language, and widely used nomenclature systems for drugs relevant to the CPIC guideline (see https://cpicpgx.org/guidelines/cpic-guideline-for-statins/).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}


Question: According to CPIC guidelines, is there an increased myopathy risk with normal dose atorvastatin in patients with  SLCO1B1 increased function, will decreased dose alleviate myopathy? Cite sources.
Answer: The provided information does not include specific guidelines for patients with SLCO1B1 increased function. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines mentioned in the prompt discuss the implications of decreased function or poor function of SLCO1B1 on atorvastatin therapy. For patients with decreased function, it is recommended to prescribe ≤40 mg as a starting dose of atorvastatin and adjust doses based on disease-specific guidelines. For patients with poor function, a starting dose of ≤20 mg is recommended. In both cases, there is a potential increased risk for myopathy. However, the guidelines do not provide specific recommendations for patients with increased function of SLCO1B1. Therefore, I do not have the necessary information to provide a response regarding the myopathy risk with normal dose atorvastatin in patients with SLCO1B1 increased function or whether a decreased dose would alleviate myopathy in such cases. 

{"Sources": "Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072."}
Sources:
page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='15 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Portions of this figure have been reproduced from reference (82) (Niemi et al) with permission from the author (MN), the publisher, the American Society for Pharmacology and Experimental Therapeutics (ASPET), and Pharmacological Reviews.' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='3 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE OF CONTENTS CPIC Updates.................................................................................................................................. 4 Literature Review ............................................................................................................................ 4 Available Genetic Test Options ...................................................................................................... 5 Linking genetic variability to variability in drug-related phenotypes ............................................ 6 Levels of evidence .......................................................................................................................... 9 Strength of dosing recommendations ............................................................................................ 10 Other Considerations' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 45  (237) Shin, J., Pauly, D.F., Pacanowski, M.A., Langaee, T., Frye, R.F. & Johnson, J.A. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy  31, 942-50 (2011).' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='5 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang]  CYP2C9: (fluvastatin) AND (CYP2C9) HMGCR: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (HMGCR) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang] CYP3A4/5: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (CYP3A4 OR' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='24 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Clinical ABCG2 rs2231142 (c.421C>A) is significantly associated with atorvastatin exposure. Keskitalo, et al. (2009) (21) DeGorter, et al. (2013) (22) Birmingham, et al. (2015) (101) Tsamandouras, et al. (2017) (180) Lee, et al. (2019) (106) Weak' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='1 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Supplemental Material  The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms Authors:  *Rhonda M. Cooper-DeHoff1,2,  *Mikko Niemi3,4,5, Laura B. Ramsey6,7, Jasmine A. Luzum8, E. Katriina Tarkiainen3,4,5, Robert J. Straka9, Li Gong10, Sony Tuteja11, Russell A. Wilke12, Mia Wadelius13, Eric A. Larson12, Dan M. Roden14,15, Teri E. Klein10, Sook Wah Yee16, Ronald M. Krauss17, Richard M. Turner18, Latha Palaniappan19, Andrea Gaedigk20, Kathleen M. Giacomini16, Kelly E. Caudle22, Deepak Voora23  1Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA 2Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA 3Department of' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content="2 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  18The Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK 19Division of Primary Care and Population Health, Stanford University School of Medicine, Stanford, CA, USA 20Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City and School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA 22Division of Pharmaceutical Sciences, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, USA 23Department of Medicine, Duke Center for Applied Genomics & Precision Medicine, Duke University School of Medicine, Durham, NC, USA *shared first author" metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}
page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n' metadata={'link': 'https://cpicpgx.org/guidelines/cpic-guideline-for-statins/', 'source': 'CPIC Clinical Guidelines for Statins and SLCO1B1, ABCG2 and CYP2C9'}
page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 38  (111) Prado, Y., Saavedra, N., Zambrano, T., Lagos, J., Rosales, A. & Salazar, L.A. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. Int J Mol Sci  16, 20609-19 (2015). (112) Mladenovska, K. et al. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects. Pharmazie  72, 288-95 (2017). (113) de Keyser, C.E. et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics  24, 43-51 (2014). (114) Kadam, P., Ashavaid, T.F., Ponde, C.K. & Rajani, R.M. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther  41, 329-33 (2016). (115) Couvert, P. et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to' metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}


